03 July 2026
03 July 2026
Celebrity ambassadors in pharma and medtech herald a new dawn of direct-to-consumer advertising.
This is Ipsen’s second acquisition this week, following its blockbuster Kartos buyout on 29 June.
The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies.
The deal could include further milestone payments, potentially bringing the total value to approximately $600m.
The ROTOR platform will initially be developed and validated using rotavirus vaccine datasets.
The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence.
Combining whole genome data with AimedBio’s drug development approach is expected to speed up clinical development.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
